checkAd
NewsFlashAnzeige
„BEST IN CLASS AKTIEN“ sind echte RENDITE-BRINGER! Investieren, zurücklehnen und Gewinne machen!

Chart

Neuigkeiten

ZeitTitel
SmartbrokerSmartbroker: Ab 0€ pro Order handeln mit dem Testsieger (Finanztest 11/2020) Anzeige
28.04.21
NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors
04.03.21
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results
02.03.21
NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer
25.02.21
NGM Bio to Present at the Cowen 41st Annual Health Care Conference
09.02.21
NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition
12.01.21
NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology
06.01.21
NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock
04.01.21
NGM Bio Announces Proposed Offering of Common Stock
09.12.20
NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors
16.11.20
NGM to Host Virtual R&D Day on December 9, 2020
13.11.20
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual
12.11.20
NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results
11.11.20
NGM Bio to Present at Three Upcoming Investor Conferences
06.05.20
Diskussion: NASH, eine schwer zu behandelnde Volkskrankheit
Avatar mogge67 schrieb:
Super Artikel https://seekingalpha.com/article/4343544-ngm-biopharmaceutic… NGM …
Insidertrade: :
Hier Upload von Dokumenten / Links zum Wertpapier: Upload

Branchen News: Pharmaindustrie

ZeitTitel
01:08 Uhr
CCXI INVESTOR NEWS: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages ChemoCentryx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – CCXI
00:00 Uhr
Glaukos Expands its PRESERFLO MicroShunt Relationship with Santen via New License Agreement
18.05.21
Indischer Impfstoffproduzent: Exportstopp könnte bis Ende 2021 dauern
18.05.21
DermTech Management to Participate in Upcoming Investor Conferences
18.05.21
The Estée Lauder Companies Increases Ownership in DECIEM
mehr Branchennachrichten »

Aktienkurs

BörsenplatzNasdaq
Letzter Kurs28,41USD
Performance-0,66 %
Kurszeit02:00:00
Eröffnung28,61USD
Tageshoch30,13USD
Tagestief28,28USD
Vortageskurs28,60USD
Volumen181,77 Tsd.Stk.
52-Wochen Hoch32,12USD
52-Wochen Tief14,930USD
Anzahl Trades928
Performance 1 Monat+9,63 %
Performance 1 Jahr+29,44 %

Stammdaten

NameNGM Biopharmaceuticals Inc
KurznameNGM Biopharma
NamenszusatzRegistered Shs
KategorieAktien
AktientypStammaktien
WKNA2N7B5
SymbolNGM
BranchePharmaindustrie
LandUSA USA
ReferenzwährungUSD
Aktienanzahl77,02 Mio.
Marktkapitalisierung2,19 Mrd.USD

Performance

ZeitKursPerf.
1 Tag28,41USD
-0,66 %
1 Woche26,77USD
+6,76 %
1 Monat26,07USD
+9,63 %
3 Monate29,17USD
-2,02 %
6 Monate20,500USD
+39,41 %
Lfd. Jahr30,30USD
-5,66 %
1 Jahr22,080USD
+29,44 %
mehr Performancedaten »

Kontaktdaten

NameNGM Biopharmaceuticals Inc
StadtSan Francisco, CA
LandUSA USA
Webseitewww.ngmbio.com

Aktionäre interessieren sich auch für:

#WertpapierPerf. %
1.
Biodelivery Sciences International
-1,10
2.
Illumina
+1,81
3.
US Physical Therapy
+0,45
4.
BB Biotech
-2,03
5.
Catalent
-1,20
6.
Coherus BioSciences
-2,12
7.
Recce Pharmaceuticals
+3,28
8.
Avadel Pharmaceuticals
+1,66
9.
Elanco Animal Health
+0,83
10.
CloudMD Software & Services
-0,54

Emission

Ausgabepreis14,00USD - 16,00USD
Emissionspreis16,000USD
Emissionsvolumen6.666.667Stück
ZeichnungsgebührNein
IPO Anmeldetag28.09.2018
IPO04.04.2019
PlatzierungÖffentlich